View Older Stories View More Recent Stories

Dec 9, 2021 04:00AM Illumina Supports Norway's Pioneering Precision Medicine Study
Nov 17, 2021 04:05PM Illumina and Sequoia Capital China Select First Startups to join Genomics Incubator in China
Nov 16, 2021 11:15AM Illumina and Genetic Alliance Launch $120 Million Global Initiative to Increase Equity and Improve Outcomes for Families Impacted by Genetic Disease
Nov 4, 2021 04:05PM Illumina Reports Financial Results for Third Quarter of Fiscal Year 2021
Nov 3, 2021 04:05PM Illumina Supports Canada's Nationwide COVID-19 Genome Sequencing Initiative
Oct 27, 2021 03:05AM Illumina Supports Israel's National Program to Accelerate Diagnoses of Critically-Ill Newborns with Suspected Genetic Disease
Oct 20, 2021 06:00PM Illumina to Host Inaugural ESG Investor Event on Tuesday, November 16, 2021
Oct 18, 2021 06:00AM Vizgen Appoints Dale Levitzke as Senior VP Global Sales and Support
Oct 15, 2021 05:35AM Illumina (ILMN) Appoints Bob Ragusa as CEO of GRAIL
Oct 14, 2021 07:35PM Illumina Appoints Bob Ragusa as Chief Executive Officer (CEO) of GRAIL
Oct 13, 2021 05:00PM Illumina to Announce Third Quarter 2021 Financial Results on Thursday, November 4, 2021
Sep 30, 2021 09:17AM Illumina (ILMN) Expands Presence in Latin America
Sep 30, 2021 09:15AM Illumina Expands Presence in Latin America
Sep 27, 2021 11:08AM Randomized trial demonstrates whole-genome sequencing leads to precision care for critically ill infants
Sep 15, 2021 09:15AM Illumina Accelerator Invests in Seven Genomics Startups for Third Global Cycle
Sep 9, 2021 09:30AM Illumina Commits to Net Zero Global Greenhouse Gas Emissions by 2050
Sep 7, 2021 09:15AM Illumina (ILMN) Partners with Merck (MRK) to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations
Sep 7, 2021 09:15AM Illumina Partners with Merck to Develop and Commercialize Companion Diagnostic and Research Tests for Use in Identifying Specific Cancer Mutations
Aug 30, 2021 05:00PM Illumina To Webcast Upcoming Investor Conference
Aug 18, 2021 04:40PM Illumina (ILMN) Acquires GRAIL
Aug 18, 2021 04:38PM Illumina Acquires GRAIL to Accelerate Patient Access to Life-Saving Multi-Cancer Early-Detection Test
Aug 5, 2021 04:05PM Illumina Reports Financial Results for Second Quarter of Fiscal Year 2021
Aug 3, 2021 09:30PM Illumina Donates $1 Million in Sequencing Capabilities to Mumbai to Support Sequencing-Based COVID-19 Surveillance in India
Jul 28, 2021 06:30PM Illumina to Webcast Upcoming Investor Conference
Jul 22, 2021 12:49PM Illumina is Committed to Bringing Lifesaving GRAIL Test to People Globally as European Review Process Enters Second Phase
Jul 13, 2021 05:00PM Illumina to Announce Second Quarter 2021 Financial Results on Thursday, August 5, 2021
Jun 10, 2021 08:00AM DNA Data Storage Alliance Publishes First White Paper, Launches Website
Jun 1, 2021 03:05AM Illumina Supports Nationwide Program across Belgium to Assess Whole Genome Sequencing for Developmental Disorders Diagnosis
May 31, 2021 04:00PM Illumina and Next Generation Genomic Partner to Launch VeriSeq™ NIPT Solution in Thailand
May 27, 2021 05:00PM Illumina To Webcast Upcoming Investor Conference
May 17, 2021 08:05AM Illumina Appoints Susan Tousi as Chief Commercial Officer and Dr. Alex Aravanis as Chief Technology Officer, Head of Research and Product Development
Apr 29, 2021 05:30PM Illumina To Webcast Upcoming Investor Conference
Apr 29, 2021 09:10AM Illumina (ILMN) Files Action for Annulment of European Commission’s Decision Asserting Jurisdiction to Review GRAIL Acquisition
Apr 29, 2021 09:05AM Illumina Files Action for Annulment of European Commission’s Decision Asserting Jurisdiction to Review GRAIL Acquisition
Apr 28, 2021 09:05AM Illumina to Donate US $60 Million in Sequencing Capabilities to Establish a Global Pathogen Genomics Initiative
Apr 27, 2021 04:05PM Illumina Reports Financial Results for First Quarter of Fiscal Year 2021
Apr 22, 2021 04:15PM Illumina (ILMN) and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic
Apr 22, 2021 04:05PM Illumina and Kartos Therapeutics Announce New Oncology Partnership to Develop an NGS-Based TP53 Companion Diagnostic
Apr 20, 2021 06:38AM Illumina (ILMN) Says it Remains Committed to GRAIL Acquisition
Apr 20, 2021 06:30AM Illumina Remains Committed to GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
Apr 5, 2021 04:32PM Illumina (ILMN) Prelim. Q1 Revenue Tops Consensus
Apr 5, 2021 04:30PM Illumina Announces Preliminary Revenue for First Quarter Fiscal Year 2021
Mar 30, 2021 03:17PM Illumina (ILMN) Says it's Committed to Pursuing GRAIL Acquisition
Mar 30, 2021 03:17PM Illumina Committed to Pursuing GRAIL Acquisition to Accelerate Access to Breakthrough Multi-Cancer Early Detection Blood Test
Mar 18, 2021 04:10PM Illumina (ILMN) announces Jay Flatley to step down from Board and John W. Thompson will be appointed as new Chair
Mar 18, 2021 04:05PM Illumina Announces Board Changes
Mar 16, 2021 10:00AM Geneseeq Inks Deal with Illumina to Develop and Commercialize Comprehensive Cancer In-vitro Diagnostic NGS Kit in China
Mar 11, 2021 04:05PM Illumina and Harvard Pilgrim Health Care Real-World Evidence Study Demonstrates Cost-Effectiveness of Offering NIPT to All Pregnant Women
Mar 5, 2021 01:00AM Illumina and R-Pharm Secure Registration for Two Complete IVD Sequencing Platforms in Russia
Feb 19, 2021 01:00AM Illumina and the University Hospital of Tübingen Evaluate Potential of Whole Genome Sequencing to Improve Diagnosis of Full Range of Genetic Diseases
View More Recent Stories View Older Stories